例如："lncRNA", "apoptosis", "WRKY"

NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.

Cell Death Dis. 2020 Jul 18;11(7):547
Lili Jiang 1 , Liangliang Ren 2 , Han Chen 3 , Jinyuan Pan 3 , Zhuojun Zhang 3 , Xiangqin Kuang 3 , Xuhong Chen 3 , Wenhao Bao 3 , Chun Lin 3 , Zhongqiu Zhou 3 , Danping Huang 4 , Jianan Yang 5 , Hongbiao Huang 3 , Lan Wang 6 , Ning Hou 7 , Libing Song 8
Lili Jiang 1 , Liangliang Ren 2 , Han Chen 3 , Jinyuan Pan 3 , Zhuojun Zhang 3 , Xiangqin Kuang 3 , Xuhong Chen 3 , Wenhao Bao 3 , Chun Lin 3 , Zhongqiu Zhou 3 , Danping Huang 4 , Jianan Yang 5 , Hongbiao Huang 3 , Lan Wang 6 , Ning Hou 7 , Libing Song 8
+ et al

[No authors listed]

Author information
  • 1 Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University, 511436, Guangzhou, China. jianglili@gzhmu.edu.cn.
  • 2 Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, 510080, Guangzhou, China.
  • 3 Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University, 511436, Guangzhou, China.
  • 4 Department of Ultrasonography, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 510623, Guangzhou, China.
  • 5 Department of Urologic Oncosurgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
  • 6 Department of Pathogen Biology and Immunology, School of Basic Courses, Guangdong Pharmaceutical University, 510006, Guangzhou, China.
  • 7 Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, 511436, Guangzhou, China.
  • 8 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060, Guangzhou, China. songlb@sysucc.org.cn.

摘要

HER2+ breast cancer (BC) is characterized by rapid growth, early recurrence, early metastasis, and chemoresistance. Trastuzumab is the most effective treatment for HER2+ BC and effectively reduces the risk of recurrence and death of patients. Resistance to trastuzumab results in cancer recurrence and metastasis, leading to poor prognosis of HER2+ BC. In the present study, we found that non-structural maintenance of chromosome condensin 1 complex subunit G (NCAPG) expression was highly upregulated in trastuzumab-resistant HER2+ BC. Ectopic NCAPG was positively correlated with tumor relapse and shorter survival in HER2+ BC patients. Moreover, overexpression of NCAPG promoted, while silencing of NCAPG reduced, the proliferative and anti-apoptotic capacity of HER2+ BC cells both in vitro and in vivo, indicating NCAPG reduces the sensitivity of HER2+ BC cells to trastuzumab and may confer trastuzumab resistance. Furthermore, our results suggest that NCAPG triggers a series of biological cascades by phosphorylating SRC and enhancing nuclear localization and activation of To summarize, our study explores a crucial role for NCAPG in trastuzumab resistance and its underlying mechanisms in HER2+ BC, and suggests that NCAPG could be both a potential prognostic marker as well as a therapeutic target to effectively overcome trastuzumab resistance.

© 2017 biocloud.net版权所有 ICP证：京10042835号